1. Significance of AZD1152 as a potential treatment against Aurora B overexpression in acute promyelocytic leukemia

   • Samad Ghanizadeh-Vesali
   • Ali Zekri
   • Seyed H. Ghaffari

   Original Article 19 April 2016 Pages: 1031 - 1042

   

2. Mutational analysis of JAK2, CBL, RUNX1, and NPM1 genes in familial aggregation of hematological malignancies

   • Walid S. Hamadou
   • Violaine Bourdon
   • Zohra Soua

   Original Article 23 April 2016 Pages: 1043 - 1050

   

3. Low-dose decitabine plus all-trans retinoic acid in patients with myeloid neoplasms ineligible for intensive chemotherapy

   • Wei Wu
   • Yan Lin
   • Weiying Gu

   Original Article 26 April 2016 Pages: 1051 - 1057

   

4. Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study

   • Francesco Buccisano
   • Anna Lina Piccioni
   • on behalf of GROM (Gruppo Romano Mielodisplasie)

   Original Article 19 April 2016 Pages: 1059 - 1065

   

5. Correlation between ‘H’ blood group antigen and Plasmodium falciparum invasion

   • Vrushali Pathak
   • Roshan Colah
   • Kanjaksha Ghosh

   Original Article 12 April 2016 Pages: 1067 - 1075

   

6. Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia

   • Ann Janssens
   • Francesco Rodeghiero
   • Janet Franklin

   Original Article Open access 30 April 2016 Pages: 1077 - 1087

   

7. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines

   • María Luisa Lozano
   • N. Revilla
   • V. Vicente

   Original Article 21 April 2016 Pages: 1089 - 1098

8. Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease

   • Rong Fu
   • Fengping Peng
   • Zonghong Shao

   Original Article 27 April 2016 Pages: 1099 - 1106

   

9. Bendamustine plus rituximab versus R-CHOP as first-line treatment for patients with indolent non-Hodgkin’s lymphoma: evidence from a multicenter, retrospective study

   • Patrizia Mondello
   • Normann Steiner
   • Michael Mian

   Original Article 22 April 2016 Pages: 1107 - 1114

   

10. Prevalence of clarithromycin-resistant Helicobacter pylori strains in gastric mucosa-associated lymphoid tissue lymphoma patients

    • Ceren Bilgilier
    • Ingrid Simonitsch-Klupp
    • Christoph Steininger

    Original Article Open access 19 April 2016 Pages: 1115 - 1120

11. Modified BEAM with triple autologous stem cell transplantation for patients with relapsed aggressive non-Hodgkin lymphoma

    • Karin Hohloch
    • Samira Zeynalova
    • Norbert Schmitz

    Original Article 11 May 2016 Pages: 1121 - 1128

    

12. High-dose ifosfamide and mitoxantrone (HDIM) in patients with relapsed or refractory Hodgkin’s lymphoma

    • Igor Aurer
    • Damir Nemet
    • Boris Labar

    Original Article 22 April 2016 Pages: 1129 - 1136

    

13. A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapy

    • Farrukh T. Awan
    • Jeffrey A. Jones
    • Leslie A. Andritsos

    Original Article 27 April 2016 Pages: 1137 - 1143

    

14. The clinical features of fatal cyclophosphamide-induced cardiotoxicity in a conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT)

    • Shinya Ishida
    • Noriko Doki
    • Kazuteru Ohashi

    Original Article 15 April 2016 Pages: 1145 - 1150

    

15. Non-myeloablative conditioning for lower-risk myelodysplastic syndrome with bone marrow blasts less than 5 %—a feasibility study

    • Eun-Ji Choi
    • Je-Hwan Lee
    • Kyoo-Hyung Lee

    Original Article 22 April 2016 Pages: 1151 - 1161

    

16. The role of thromboelastography in predicting bleeding risk and guiding the administration of platelet transfusions in hematological patients: a cohort study

    • Xing Xin
    • Zhaojun Liu
    • Dengju Li

    Original Article 12 April 2016 Pages: 1163 - 1168

    

17. Procalcitonin-guided protocol is not useful to manage antibiotic therapy in febrile neutropenia: a randomized controlled trial

    • Stella Sala Soares Lima
    • Vandack Nobre
    • José Carlos Serufo

    Original Article 27 April 2016 Pages: 1169 - 1176

    

18. Communication during haematological consultations; patients’ preferences and professionals’ performances

    • Inge R. van Bruinessen
    • Lotte E. van der Hout
    • Sandra van Dulmen

    Original Article 18 April 2016 Pages: 1177 - 1183

19. Pruritus in primary myelofibrosis: management options in the era of JAK inhibitors

    • Brianna E. Vaa
    • Ayalew Tefferi
    • Alexandra P. Wolanskyj

    Original Article 23 April 2016 Pages: 1185 - 1189

20. Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation

    • Yok-Lam Kwong

    Letter to the Editor 28 March 2016 Pages: 1191 - 1192

    

21. Amisulpride induced agranulocytosis: a case report

    • Lucy Pickard
    • Nicholas Fordham
    • Mickey Koh

    Letter to the Editor 07 April 2016 Pages: 1193 - 1195

    

22. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia

    • Maximilian Stahl
    • Mina L. Xu
    • Amer M Zeidan

    Letter to the Editor 11 April 2016 Pages: 1197 - 1200

    

23. Influence of single nucleotide polymorphisms in the BCL11A and HBS1L-MYB gene on the HbF levels and clinical severity of sickle cell anaemia patients

    • Dipti Upadhye
    • Dipty Jain
    • Roshan Colah

    Letter to the Editor 20 April 2016 Pages: 1201 - 1203

24. Early-onset chronic lymphocytic leukaemia in a young man with Cowden syndrome

    • C. Molloy
    • R. Cahill
    • J. Quinn

    Letter to the Editor 11 May 2016 Pages: 1205 - 1206

25. Use of rifampin for treatment of disseminated tuberculosis in a patient with primary myelofibrosis on ruxolitinib

    • Benoit Branco
    • David Metsu
    • Guillaume Martin-Blondel

    Letter to the Editor 26 April 2016 Pages: 1207 - 1209